摘要
目的探讨流式细胞术(FCM)检测肿瘤相关基因P16蛋白表达的应用价值。方法用人白细胞共同抗原45(CD45)和P16荧光标记抗体同步标记肺穿刺肿瘤标本中血细胞和肿瘤细胞的P16蛋白,经FCM测定CD45+P16+和CD45-P16+细胞比率后,对每份穿刺标本血细胞P16+与肿瘤细胞P16+细胞的比值(r)进行比较。结果肺癌患者39份穿刺标本中正常血细胞与肿瘤细胞的P16蛋白低表达率分别是15·39%(6/39)和69·23%(27/39),二者差异有统计学意义(P<0·05)。61·90%(13/21)的异倍体肿瘤r>4;22·22%(4/18)的二倍体肿瘤r>4,两组间差异有统计学意义(P<0·05)。结论FCM可同步测定血细胞与肿瘤细胞P16蛋白表达水平,并可比较区分出表达程度的差异性,在临床科研应用中有较好的前景。
Objective To improve the sensitivity of detection of protein P16 by FCM. Methods Protein P16 of blood cells and tumor cells in biopsy samples were labeled simultaneously with anti-CIM5 and anti-P16 fluorescent antibody. The rates of CIM5^＋P16^＋ cells and CIM5^- P16^＋ cells were calculated by FCM. Results The low expression rates of protein P16 in normal blood cells and in tumor cells in biopsy samples were 15.39% （6/39） and 69. 23% （27/39）, respectively, which had a significant differences （ P 〈 0. 05 ）. The ratio （r） of CD45^＋ P16^＋ cells to CD45^- P16^＋ cells in each sample was calculated. R value more than 4 was observed in 61.90% （13/21） aneuploid tumors and in 22.22% （4/18） diploid tumors, respectively, which had a significant difference （ P 〈 0. 05 ）. Conclusion FCM can be used to test the protein expression levels in different cells and compare the expression differences between them.It may have a bright clinical and scientific application prospect.
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2005年第10期1051-1053,共3页
Chinese Journal of Laboratory Medicine
